$222 Billion is the total value of RTW INVESTMENTS, LP's 24 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 36.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DYAX | Sell | Dyax Corp | $26,558,000 | -11.4% | 1,585,098 | -25.6% | 11.99% | +8.1% |
| DRNA | Sell | Dicerna Pharmaceuticals Inc | $23,813,000 | +29.6% | 990,981 | -11.2% | 10.75% | +58.1% |
| ARWR | Sell | Arrowhead Research Corp | $16,304,000 | -15.4% | 2,410,000 | -7.7% | 7.36% | +3.3% |
| ZSPH | Sell | ZS Pharma Inc | $3,001,000 | -80.7% | 71,315 | -81.0% | 1.36% | -76.5% |
| CYTR | Sell | CytRx Corp | $1,900,000 | -1.7% | 563,814 | -20.0% | 0.86% | +20.0% |
| TARO | Sell | Taro Pharmaceutical Industries Ltd | $1,230,000 | -96.9% | 8,721 | -96.7% | 0.56% | -96.2% |
| RLYP | Sell | Relypsa Inc | $1,150,000 | -91.7% | 31,872 | -92.9% | 0.52% | -89.9% |
| NVRO | Exit | NEVRO CORP | $0 | – | -15,356 | -100.0% | -0.22% | – |
| PLX | Exit | PROTALIX BIOTHERAPEUTICS INC | $0 | – | -843,851 | -100.0% | -0.58% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -2.65% | – |
| XNPT | Exit | XENOPORT INC | $0 | – | -842,568 | -100.0% | -2.73% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-21
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.